• -
  • English
  • Japanese
  • Korean
表紙
市場調查報告書
商品編碼
1025426

全球肺癌治療市場預測（2021-2027）

Lung Cancer Therapeutics Market 2021-2027
出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內，全球肺癌治療市場預計將以約 8.7% 的顯著複合年增長率增長。肺癌患病率的增加是肺癌市場的主要驅動力。這主要是由於肺癌患病率和患病率的增加，這增加了對能夠進行準確有效治療的藥物的需求。此外，有效的臨床試驗和 FDA 的批准是推動全球肺癌治療市場的兩個關鍵因素。 Platinol、Gemzar、Iressa、Zarcoli、Alimta、Taxol 和 Tarceva 等肺癌治療處方正在增加。

COVID-19 對肺癌治療市場產生了負面影響，因為美國疾病控制與預防中心 (CDC) 和許多醫療專業人員冒著癌症篩查和其他健康預防保健、手術等風險。建議推遲它，除非它超過收益並確保醫院設施用於治療 COVID-19 患者。 COVID-19 大流行已經影響了肺癌治療市場，但隨著時間的推移，這種情況預計會有所改善。

本報告調查和分析了全球肺癌治療市場，並提供了有關市場概況、市場決定因素、細分市場、競爭條件、區域分析、關鍵公司等的系統信息。

目錄

第 1 章報告概述

第 2 章市場概覽和洞察

  • 調查範圍
  • 分析師洞察和最新市場趨勢
  • 監管

第三章競爭形勢

  • 主要公司分析
    • 概述
    • 財務分析
    • SWOT 分析
  • 主要戰略分析
  • COVID-19 對大公司的影響

第 4 章市場決定因素

  • 增長因素
  • 抑製器
  • 市場機會

第 5 章市場細分

  • 按藥物分列的全球肺癌治療市場
    • 鉑金
    • 紫杉醇
    • 傑姆扎爾
    • 阿力達
    • 其他（易瑞沙、High Kamchin、Guillotriff、Taxotere、Zarkoli）
  • 按治療分類的全球肺癌治療市場
    • 化療
    • 靶向治療
    • 免疫療法
    • 放射治療
    • 其他
  • 按最終用戶劃分的全球肺癌治療市場
    • 多專科醫院
    • 癌症研究中心

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他領域

第 7 章公司簡介

  • Abbvie Inc.
  • Achieve Life Sciences, Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics, Inc
  • Eisai Co Ltd
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Glaxosmithkline Plc
  • Helsinn Healthcare S.A.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2023858

Full-title:Global Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drugs ( Platinol, Taxol, Gemzar, Alimta, and Others) By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, and Others ), By End-User (Multispeciality Hospitals, Cancer Research Centers) Forecast, 2021-2027.

The global market for lung cancer therapeutics is projected to have a considerable CAGR of around 8.7% during the forecast period. The rising prevalence of lung cancer is a major driving factor in the lung cancer market. This is primarily due to an increase in the prevalence and incidence rate of lung cancer cases, which drives the need for drugs that allow for accurate and effective treatment of the disease. Further, effective clinical trials and FDA approval are also the two most important factors driving the global lung cancer therapeutics market. Prescriptions for lung cancer therapeutics such as Platinol, Gemzar, Iressa, Xalkori, Alimta, Taxol, and Tarceva are increasing.

The COVID-19 negatively impacted the lung cancer therapeutics market as the Centers for Disease Control and Prevention (CDC) and many medical professional organizations advised that cancer screening and other health preventive care, as well as surgical procedures, be postponed unless the risks outweighed the benefits, and that hospital facilities be secured for the treatment of COVID-19 patients. As a result of the COVID-19 pandemic, the lung cancer therapy market has been impacted, however, the situation is expected to gradually improve.

The global Lung Cancer Therapeutics market is segmented based on drugs, therapy, and end-user.  Based on drugs, the market is segmented into Platinol, Taxol, Gemzar, Alimta, and others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori). Based on therapy, the market is classified into chemotherapy, targeted therapy, immunotherapy, radiation therapy, and others. Further, based on end-user, the market is segregated into multispeciality hospitals, cancer research centres. The targeted therapy segment is expected to have a significant share of the global market, as traditional chemotherapy can cause harm to normal cells while killing cancer cells, the demand for targeted therapy is expected to rise over the forecasted period. 

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Asia-Pacific is the fastest-growing market for lung cancer therapeutics. The growth is attributed to the increasing prevalence of lung cancer due to factors such as unhealthy maintenance of diets, the growing ageing population, environmental populations. Additionally, cigarette smoking, in particular, has remained widespread in the Asia-Pacific region. As a result of the rising prevalence of lung cancer, the market is expected to grow during the forecast period. The key players of the lung cancer therapeutics market include AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others.

Research Methodology

The market study of the global lung cancer therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Lung Cancer Therapeutics Market Research and Analysis by Drugs
  • Global Lung Cancer Therapeutics Market Research and Analysis by Therapy
  • Global Lung Cancer Therapeutics Market Research and Analysis by End-user

The Report Covers

  • Comprehensive research methodology of the global lung cancer therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Lung Cancer Therapeutics market.
  • Insights about market determinants that are stimulating the global Lung Cancer Therapeutics market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Lung cancer therapeutics Industry
  • Recovery Scenario of Global Lung cancer therapeutics Industry
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Lung Cancer Therapeutics Marketby Drugs
    • 5.1.1. Platinol
    • 5.1.2. Taxol
    • 5.1.3. Gemzar
    • 5.1.4. Alimta
    • 5.1.5. Others (Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori)
  • 5.2. Global Lung cancer therapeutics marketby Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Immunotherapy
    • 5.2.4. Radiation Therapy
    • 5.2.5. Others
  • 5.3. Global Lung cancer therapeutics marketbyEnd-User
    • 5.3.1. Multispeciality Hospitals
    • 5.3.2. Cancer Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbvie Inc.
  • 7.2. Achieve Life Sciences, Inc.
  • 7.3. Amgen Inc.
  • 7.4. AstraZeneca Plc
  • 7.5. Astellas Pharma Inc.
  • 7.6. Boehringer Ingelheim International GmbH
  • 7.7. Bristol-Myers Squibb Co.
  • 7.8. Celldex Therapeutics, Inc
  • 7.9. Eisai Co Ltd
  • 7.10. Eli Lilly and Co.
  • 7.11. F. Hoffmann-La Roche Ltd.
  • 7.12. Glaxosmithkline Plc
  • 7.13. Helsinn Healthcare S.A.
  • 7.14. Novartis International AG
  • 7.15. Pfizer, Inc.
  • 7.16. Sanofi SA
  • 7.17. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS,2020-2027 ($ MILLION)
  • 2. GLOBALPLATINOL FORLUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL TAXOL FORLUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL GEMZARFOR LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL ALIMTAFORLUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL OTHER DRUGS FOR LUNG CANCERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBALLUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 8. GLOBAL CHEMOTHERAPY FOR LUNG CANCERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL TARGETED THERAPYFOR LUNG CANCERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL IMMUNOTHERAPYFOR LUNG CANCERMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RADIATION THERAPYFOR LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL OTHER THERAPYLUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BYEND-USER, 2020-2027 ($ MILLION)
  • 14. GLOBALLUNG CANCER THERAPEUTICS INMULTISPECIALITY HOSPITALSMARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 15. GLOBALLUNG CANCER THERAPEUTICS INCANCER RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 16. GLOBAL LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 17. NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 18. NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS,2020-2027 ($ MILLION)
  • 19. NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027 ($ MILLION)
  • 20. NORTH AMERICAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BYEND-USER, 2020-2027 ($ MILLION)
  • 21. EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 22. EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUGS,2020-2027 ($ MILLION)
  • 23. EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 24. EUROPEAN LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 25. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 26. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSISBY DRUGS,2020-2027 ($ MILLION)
  • 27. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 28. ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BYEND-USER, 2020-2027 ($ MILLION)
  • 29. REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 30. REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSISBY DRUGS2020-2027 ($ MILLION)
  • 31. REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 32. REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER THERAPEUTICS MARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL LUNG CANCER THERAPEUTICS MARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL LUNG CANCER THERAPEUTICS MARKET, 2020-2027 (%)
  • 4. GLOBAL LUNG CANCER THERAPEUTICS MARKETSHARE BY DRUGS,2020 VS 2027 (%)
  • 5. GLOBAL LUNG CANCER THERAPEUTICS MARKETSHARE BY THERAPY, 2020 VS 2027 (%)
  • 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET SHARE BY END-USER 2020 VS 2027 (%)
  • 7. GLOBAL LUNG CANCER THERAPEUTICS MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL PLATINOL FORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL TAXOLFORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL GEMZARFORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL ALIMTAFORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL OTHERS LUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBALCHEMOTHERAPYFORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBALTARGETED THERAPYFORLUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL IMMUNOTHERAPYFOR LUNG CANCER THERAPEUTICSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL RADIATION THERAPYFOR LUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL OTHERS LUNG CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBALLUNG CANCER THERAPEUTICS INMULTISPECIALITY HOSPITALSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. GLOBAL LUNG CANCER THERAPEUTICS IN CANCER RESEARCH CENTERSMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 20. US LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 21. CANADA LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 22. UK LUNG CANCER THERAPEUTICS MARKET SIZE, 2020-2027($ MILLION)
  • 23. FRANCE LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 24. GERMANY LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 25. ITALY LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 26. SPAIN LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 27. REST OF EUROPE LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 28. INDIA LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 29. CHINA LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 30. JAPAN LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 31. SOUTH KOREA LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 32. REST OF ASIA-PACIFIC LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)
  • 33. REST OF THE WORLD LUNG CANCER THERAPEUTICS MARKETSIZE, 2020-2027($ MILLION)